Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hansa Biopharma to Participate in Three Upcoming Investor Conferences

HNSBF

Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs' Biotech Symposium in London, Morgan Stanley's Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in London

LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences:

  • The Goldman Sachs Ninth Annual Biotech Symposium in London on Friday, September 6, 2019.
  • The Morgan Stanley 17th Annual Global Healthcare Conference in New York City, NY Tuesday, September 10, 2019, with a presentation at 1:30 PM EST/ 19:30 CET on the same day.
  • The Bank of America Merrill Lynch Global Healthcare Conference 2019 in London from Thursday, September 19, 2019 to Friday, September 20, 2019, with a presentation at 14:45 CET on Friday September 20.

A live webcast of the Morgan Stanley presentation will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

CONTACT:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com 


This information was brought to you by Cision http://news.cision.com 
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-participate-in-three-upcoming-investor-conferences,c2884759

The following files are available for download:

https://mb.cision.com/Main/1219/2884759/1092648.pdf

Hansa Biopharma to participate in three upcoming investor conferences

 

 

Cision View original content:http://www.prnewswire.com/news-releases/hansa-biopharma-to-participate-in-three-upcoming-investor-conferences-300904967.html

SOURCE Hansa Biopharma AB



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today